Browsing by Author "Johnny Mahlangu"
Now showing 1 - 15 of 15
Results Per Page
Sort Options
Item Application fo fa hemophila mortality framework to the Emicizumab Global Safety DatabaseFlora Peyvandi; Johnny Mahlangu; Steven Pipe; Charles Hay; Glenn Pierce; Peter Kuebler; R Kruse-Jarres; M ShimaItem Bleeding events and safety outcomes in persons with haemophilia A with inhibitors A prospective multicentre noninterventional studyJohnny Mahlangu; J Oldenburg; Michael Callaghan; Midori Shima; Elena Santagostino; E et alItem Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa and IndiaKenneth Cornetta; Martin Bonamino; Johnny Mahlangu; Federico Mingozzi; S Rangarajan; J RaoItem Healthrelated quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors A non interventional studyJ Oldenburg; Huyen Tran; Flora Peyvandi; Ramiro Nunez; Peter Trask; S Chebon; Johnny Mahlangu; M Lehle; V JIMENEZ-YUSTE; S Von MackensenItem Immunoglobulin subtying and quantification in direct antiglobun test positive heamolysis in an HIVprevalent settingThirosha Chetty; Nikki Bouwer; Yuen On Wan; Johnny MahlanguItem Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion proteinJ Oldenburg; R Kulkarni; A SRIVASTAVA; Johnny Mahlangu; V BLANCHETTE; E et alItem Managing surgery in hemophilia with recombinant factor VII Fc and factor IX Fc Data on safety and effectiveness from phase 3 pivotal studiesP Chowdary; Margareta Holmstrom; Johnny Mahlangu; M OZELO; I Pabinger; E et alItem PERSEPT 3 A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta recombinant human FVIIa in perioperative care in subjects with haemophilia A or B with inhibitorsM Escobar; J Luck; Y Averianov; J Ducore; M Fernandez; Johnny MahlanguItem Prophylaxis is the new standard of care in patients with haemophiliaJohnny Mahlangu; F Bassa; Mairi Bassingthwaighte; A Cruickshank; J du Plessis; Y Goga; Ngoakoana Mahlachana; E et alItem Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A Final results from the ASPIRE extension studyBeatrice Nolan; Johnny Mahlangu; Ingrid Pabinger; Guy Young; Barbara Konkle; A Et AlItem RECOMBINANT SINGLECHAIN FACTOR VIII IN SEVERE HEMOPHILIALONGTERM SAFETY AND EFFICACY IN PREVIOUSLY TREATED PATIENTS IN THE AFFINITY EXTENSION STUDYJohnny Mahlangu; F Karim; O Stasyshyn; B Korczowski; Blanca Salazar; E et alItem Redefining prophylaxis in the modern eraJohnny Mahlangu; V BLANCHETTE; R KlamrothItem Subcutaneous engineered factor VIIa marzeptacog alfaactivated n hemophilia with inhibitorsPhase 2 trial of pharmacokinetics pharmacodynamics efficacy and safetyJohnny Mahlangu; Howard Levy; Marina Kosinova; Heghine Khachatryan; Bartosz KorczowskiItem Valoctocogene Roxaparvovec Gene Therapy for Hemophilia AM OZELO; Johnny Mahlangu; K Pasi; A Giermasz; S leavitt; E et al